Eagle Pharmaceuticals Rating Reiterated by Cantor Fitzgerald (EGRX)
Eagle Pharmaceuticals (NASDAQ:EGRX)‘s stock had its “buy” rating reiterated by analysts at Cantor Fitzgerald in a research report issued to clients and investors on Wednesday. They currently have a $30.00 price target on the stock, up from their previous price target of $22.00. Cantor Fitzgerald’s price target indicates a potential upside of 178.81% from the company’s current price.
Eagle Pharmaceuticals (NASDAQ:EGRX) traded up 1.95% on Wednesday, hitting $10.97. The stock had a trading volume of 9,872 shares. Eagle Pharmaceuticals has a one year low of $9.16 and a one year high of $16.44. The stock has a 50-day moving average of $12.62 and a 200-day moving average of $12.23. The company’s market cap is $153.8 million.
Eagle Pharmaceuticals (NASDAQ:EGRX) last announced its earnings results on Monday, August 11th. The company reported ($0.21) EPS for the quarter, beating the Thomson Reuters consensus estimate of ($0.37) by $0.16. The company had revenue of $5.80 million for the quarter, compared to the consensus estimate of $3.40 million. On average, analysts predict that Eagle Pharmaceuticals will post $-1.25 earnings per share for the current fiscal year.
Eagle Pharmaceuticals, Inc (NASDAQ:EGRX) is a specialty pharmaceutical company.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.